Lakewood-Amedex shares gain momentum as the company reports successful clinical data for its Nu-3 Bisphosphocin candidate, targeting the treatment of diabetic foot ulcers with reduced resistance risks.
Positive data for Nu-3 against diabetic foot ulcer isolates is a bullish catalyst for the company's stock.
Lakewood-Amedex Biotherapeutics announced promising clinical data for its lead candidate, Nu-3, a topically formulated Bisphosphocin. The drug demonstrates rapid antimicrobial efficacy against diabetic foot ulcer isolates while minimizing the risk of resistance.
Nu-3 is a topically formulated Bisphosphocin designed to rapidly eliminate microbes in diabetic foot ulcers while mitigating the development of antimicrobial resistance.